Syncytial

HEALTH

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season – Merck.com

June 9, 2025

13

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born…

HEALTH

WHO outlines recommendations to protect infants against RSV – respiratory syncytial virus – World Health Organization (WHO)

May 30, 2025

17

WHO outlines recommendations to protect infants against RSV – respiratory syncytial virus World Health Organization (WHO) Key Takeaways to Prioritize in…

HEALTH

Interim Evaluation of Respiratory Syncytial … – Centers for Disease Control and Prevention | CDC (.gov)

May 8, 2025

14

Interim Evaluation of Respiratory Syncytial … Centers for Disease Control and Prevention | CDC (.gov) US infant mortality dropped in 2024.…